We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cyprotex Adds Service to Support Early Drug Discovery
Product News

Cyprotex Adds Service to Support Early Drug Discovery

Cyprotex Adds Service to Support Early Drug Discovery
Product News

Cyprotex Adds Service to Support Early Drug Discovery


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Cyprotex Adds Service to Support Early Drug Discovery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cyprotex has announced the launch of a service to help drug discovery groups to assess new oral drug candidates.

The service, known as Cloe Screen PAMPA (Parallel Artificial Membrane Permeation Assay) complements Cyprotex's existing portfolio of compound screens for evaluating the permeability of drug discovery compounds.

Cloe Screen PAMPA is designed to provide a way to prioritise compounds based on their potential to cross the gut wall and it is based on assessing simple permeability properties.

It enables drug researchers to see how their compounds behave in the different pH environments that exist throughout the entire gastro-intestinal tract. 

Cloe Screen PAMPA uses mass spectrometry (LC-MS/MS) as an end-point to ensure greater data accuracy and sensitivity than traditionally employed absorbance measurements.

Commenting on the launch of this new service, Dr. Darwin Cheney, Cyprotex's Chief Scientific Officer, said, "The Cloe Screen PAMPA offers our partners a high quality, fast turnaround assay that displays notable reproducibility."

"In addition, we have demonstrated that our assay shows several fold improvement in sensitivity over currently available PAMPA assays."

Advertisement